CA3135292A1 - Engineered adeno-associated (aav) vectors for transgene expression - Google Patents
Engineered adeno-associated (aav) vectors for transgene expression Download PDFInfo
- Publication number
- CA3135292A1 CA3135292A1 CA3135292A CA3135292A CA3135292A1 CA 3135292 A1 CA3135292 A1 CA 3135292A1 CA 3135292 A CA3135292 A CA 3135292A CA 3135292 A CA3135292 A CA 3135292A CA 3135292 A1 CA3135292 A1 CA 3135292A1
- Authority
- CA
- Canada
- Prior art keywords
- aav
- cell
- library
- aav9
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825703P | 2019-03-28 | 2019-03-28 | |
| US62/825,703 | 2019-03-28 | ||
| PCT/US2020/025720 WO2020198737A1 (en) | 2019-03-28 | 2020-03-30 | Engineered adeno-associated (aav) vectors for transgene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3135292A1 true CA3135292A1 (en) | 2020-10-01 |
Family
ID=72609527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3135292A Pending CA3135292A1 (en) | 2019-03-28 | 2020-03-30 | Engineered adeno-associated (aav) vectors for transgene expression |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220195458A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3947422A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7659271B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260036045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113874387B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020248116B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019436A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3135292A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286725A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011701A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202110165XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198737A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
| CA3087238A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| CN111989068B (zh) | 2018-05-24 | 2024-10-25 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| US11149256B2 (en) | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| EP3959324B1 (en) | 2019-04-26 | 2025-09-17 | President and Fellows of Harvard College | Aav vectors encoding mini-pcdh15 and uses thereof |
| AU2020366531A1 (en) * | 2019-10-18 | 2022-05-26 | Research Institute At Nationwide Children's Hospital | Gene therapy targeting cochlear cells |
| FI4103214T3 (fi) | 2020-02-13 | 2026-07-03 | Tenaya Therapeutics Inc | Geeniterapian vektorit sydänsairauden hoitoon |
| US12129287B2 (en) | 2020-09-14 | 2024-10-29 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| US20240075167A1 (en) * | 2021-02-03 | 2024-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of gene delivery to retinal astrocytes |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| TW202317768A (zh) | 2021-07-08 | 2023-05-01 | 美商特納亞治療股份有限公司 | 用於基因療法的優化表現卡匣 |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| CN114606264B (zh) * | 2022-03-22 | 2025-08-26 | 三峡大学 | 一种用于神经系统药物递送的aav病毒载体 |
| WO2024054864A1 (en) | 2022-09-06 | 2024-03-14 | Tenaya Therapeutics, Inc. | Cardioprotective heart disease therapies |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| EP4695396A1 (en) | 2023-04-10 | 2026-02-18 | Tenaya Therapeutics, Inc. | Guide rnas, vectors, and virions for targeting mutations in the pln gene |
| WO2024215655A1 (en) | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Cardioprotective bag3 therapies |
| WO2024220545A2 (en) * | 2023-04-17 | 2024-10-24 | The General Hospital Corporation | Aav capsids for on-target delivery to spinal cord |
| EP4698555A1 (en) * | 2023-04-18 | 2026-02-25 | uniQure biopharma B.V. | Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
| ES2547381T3 (es) * | 2004-04-09 | 2015-10-05 | Monsanto Technology, Llc | Composiciones y procedimientos de control de infestaciones de insectos en plantas |
| US7588772B2 (en) * | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| NZ716102A (en) * | 2013-07-22 | 2021-12-24 | The Children’S Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| EP3564379A1 (en) * | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| US10307492B2 (en) * | 2014-03-11 | 2019-06-04 | Wayne State University | Modified MGLUR6 promoter and methods of use |
| AU2016366549B2 (en) * | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| GB2545763A (en) * | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| CA3011939A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| JP6994018B2 (ja) * | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| EP4219806A3 (en) | 2017-04-11 | 2023-09-27 | Ruprecht-Karls-Universität Heidelberg | Adeno-associated virus library |
| US11512327B2 (en) * | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| MX2020001997A (es) * | 2017-08-28 | 2020-07-20 | Univ California | Variantes de capside de virus adenoasociado y metodos de uso de estas. |
| CA3092107A1 (en) * | 2018-02-28 | 2019-09-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for antibody-evading virus vectors |
| CN109207520B (zh) * | 2018-09-25 | 2022-05-10 | 北京锦篮基因科技有限公司 | Leber遗传性视神经病变的基因药物 |
-
2020
- 2020-03-30 JP JP2021557657A patent/JP7659271B2/ja active Active
- 2020-03-30 US US17/442,894 patent/US20220195458A1/en active Pending
- 2020-03-30 WO PCT/US2020/025720 patent/WO2020198737A1/en not_active Ceased
- 2020-03-30 KR KR1020267006391A patent/KR20260036045A/ko active Pending
- 2020-03-30 BR BR112021019436A patent/BR112021019436A2/pt unknown
- 2020-03-30 EP EP20779113.8A patent/EP3947422A4/en active Pending
- 2020-03-30 KR KR1020217034532A patent/KR102934700B1/ko active Active
- 2020-03-30 AU AU2020248116A patent/AU2020248116B2/en active Active
- 2020-03-30 CN CN202080038934.8A patent/CN113874387B/zh active Active
- 2020-03-30 CA CA3135292A patent/CA3135292A1/en active Pending
- 2020-03-30 SG SG11202110165XA patent/SG11202110165XA/en unknown
- 2020-03-30 MX MX2021011701A patent/MX2021011701A/es unknown
-
2021
- 2021-09-26 IL IL286725A patent/IL286725A/en unknown
-
2025
- 2025-03-19 JP JP2025044435A patent/JP2025098107A/ja active Pending
-
2026
- 2026-02-26 AU AU2026201434A patent/AU2026201434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220195458A1 (en) | 2022-06-23 |
| AU2026201434A1 (en) | 2026-03-19 |
| EP3947422A4 (en) | 2023-05-17 |
| JP7659271B2 (ja) | 2025-04-09 |
| KR102934700B1 (ko) | 2026-03-09 |
| WO2020198737A1 (en) | 2020-10-01 |
| BR112021019436A2 (pt) | 2021-12-07 |
| AU2020248116A1 (en) | 2021-10-14 |
| MX2021011701A (es) | 2021-12-10 |
| KR20260036045A (ko) | 2026-03-13 |
| JP2025098107A (ja) | 2025-07-01 |
| KR20210143869A (ko) | 2021-11-29 |
| IL286725A (en) | 2021-12-01 |
| CN113874387B (zh) | 2025-01-07 |
| AU2020248116B2 (en) | 2025-12-04 |
| EP3947422A1 (en) | 2022-02-09 |
| JP2022527917A (ja) | 2022-06-07 |
| CN113874387A (zh) | 2021-12-31 |
| SG11202110165XA (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020248116B2 (en) | Engineered adeno-associated (AAV) vectors for transgene expression | |
| RU2727672C2 (ru) | Нацеливающие пептиды для направленной доставки аденоассоциированных вирусов (aav) | |
| US20240209394A1 (en) | AAV Capsids and Uses Thereof | |
| JP7303816B2 (ja) | Aavベクター | |
| AU2020375947B2 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
| KR20190132626A (ko) | 향상된 유전자 발현을 위한 조성물 및 방법 | |
| AU2008216018B2 (en) | Mitochondrial nucleic acid delivery systems | |
| AU2017227776C1 (en) | AAV vectors for treatment of dominant retinitis pigmentosa | |
| CN108347932A (zh) | 用于治疗遗传性眼病的方法和组合物 | |
| JP2010516252A (ja) | 筋鞘にnNOSを回復させる合成ミニ/ミクロジストロフィン遺伝子 | |
| CN103764831A (zh) | 不含衣壳的aav载体、组合物以及制备载体和基因递送的方法 | |
| CN113840927A (zh) | 用于治疗核纤层蛋白病的组合物及方法 | |
| CN117642173A (zh) | 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒 | |
| KR102888699B1 (ko) | 코돈 최적화된 rep1 유전자 및 이의 용도 | |
| RU2839774C2 (ru) | Сконструированные аденоассоциированные (aav) векторы для экспрессии трансгена | |
| Egorova et al. | Adeno-associated virus vector-based gene therapy for hereditary diseases: Current problems of application and approaches to solve them | |
| JP2024517957A (ja) | ベクター系 | |
| CN118159662A (zh) | 用于治疗sod1相关疾病的crispr-cas13系统 | |
| WO2025162267A1 (zh) | 表达myo7a蛋白的双载体系统及其用途 | |
| Martin | Development and Characterisation of HEK293T Cell Expression Systems for Enhanced Production of Recombinant AAV Viral Vectors | |
| EP4698554A2 (en) | Aav capsids for on-target delivery to spinal cord | |
| WO2024165839A1 (en) | Transgenes | |
| Mason | SRSF1-mediated gene therapy as a therapeutic approach for C9ORF72-related amyotrophic lateral sclerosis and fronto-temporal dementia (ALS-FTD) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241024 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241112 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20241127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250128 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250321 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250411 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250428 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250528 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250528 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250528 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250528 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250819 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20251021 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |